CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

Judith Weiland, Alex Elder, Victoria Forster, Olaf Heidenreich, Steffen Koschmieder, Josef Vormoor

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

21 Citaten (Scopus)

Samenvatting

Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways. Pediatr Blood Cancer 2015;62:1144-1148.

Originele taal-2Engels
Pagina's (van-tot)1144-1148
Aantal pagina's5
TijdschriftPediatric Blood and Cancer
Volume62
Nummer van het tijdschrift7
DOI's
StatusGepubliceerd - 1 jul. 2015
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit